Abcuro, Inc.
Clinical trials sponsored by Abcuro, Inc., explained in plain language.
-
New hope for rare leukemia: drug ABC008 shows promise in early trial
Disease control CompletedThis study tested a new drug called ABC008 in 21 adults with a rare leukemia called T-LGLL. The main goal was to check the drug's safety and find the right dose. Researchers also looked at how the drug affected blood counts and other lab results.
Phase: PHASE1, PHASE2 • Sponsor: Abcuro, Inc. • Aim: Disease control
Last updated May 17, 2026 19:22 UTC
-
New drug shows promise for rare Muscle-Wasting disease
Disease control CompletedThis study tested a new drug called ABC008 in 272 adults with inclusion body myositis, a rare muscle disease that causes weakness. The goal was to see if the drug is safe and can help slow the disease. Participants received either the drug or a placebo, and their muscle function …
Phase: PHASE2, PHASE3 • Sponsor: Abcuro, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC